Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.11 USD
Change Today -0.0147 / -12.28%
Volume 11.5K
BJCT On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

bioject medical technologies (BJCT) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/13/14 - $0.35
52 Week Low
12/24/14 - $0.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

bioject medical technologies (BJCT) Related Businessweek News

No Related Businessweek News Found

bioject medical technologies (BJCT) Details

Bioject Medical Technologies Inc., together with its subsidiaries, develops, manufactures, and distributes needle-free injection therapy systems for the pharmaceutical and biotech industries in the United States. Its needle-free injection products include Biojector 2000 system that delivers intramuscular, subcutaneous, and intradermal injections; ZetaJet system, which provides vaccines and injectable medications either subcutaneously or intramuscularly for professional and home use; and a needle-free drug reconstitution system, which allows the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. It also offers a needle-free drug reconstitution vial adapter, a plastic device that replaces a fill needle for accessing medication vials making syringe filling completely needle-free. In addition, the company is developing Intradermal Pen spring-powered needle-free injector; Iject gas-powered and versatile injection systems; Jupiter Jet, a hand-held device for administering small volumes of drugs; and multi-port orifices for intradermal injections. Bioject Medical Technologies Inc. was founded in 1985 and is based in Tigard, Oregon.

bioject medical technologies (BJCT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bioject medical technologies (BJCT) Key Developments

Bioject Medical Technologies Inc. Reports Earnings Result for the Fourth Quarter and Year Ended December 31, 2014

Bioject Medical Technologies Inc. reported earnings result for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported net loss allocable to common shareholders of $305,000, or $0.01 per diluted share compared to a net income allocable to common shareholders of $215,000, or $0.01 loss per diluted share, for the same quarter ended December 31, 2013. Net sales were $513,000 compared to $384,000 for the same quarter ended December 31, 2013. Operating loss was $250,000 compared with income of $268,000 a year ago. For the year, the company reported net loss allocable to common shareholders of $1,141,000 million, or $0.04 loss per share, compared to a net loss allocable to common shareholders of $1,133,000 or $0.06 loss per share, for the year ended December 31, 2013. Net sales were $1,825,000 compared to $1,530,000 for the year ended December 31, 2013. Operating loss was $907,000 compared with $969,000 a year ago.

Bioject Medical Technologies Inc. announced delayed annual 10-K filing

On 03/30/2015, Bioject Medical Technologies Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Bioject Medical Technologies Inc. Announces Executive Changes

Bioject Medical Technologies Inc. has appointed Tony Chow as the president and CEO. Mr. Tony Chow was previously company's CFO. His back ground includes being the CFO at American Laser Healthcare Corporation. Mr. Mark Logomasini, the prior President and CEO, will assume the new role and title of director of business development for company.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BJCT:US $0.11 USD -0.0147

BJCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.72 USD -0.04
Becton Dickinson and Co $144.33 USD -0.02
West Pharmaceutical Services Inc $57.38 USD +0.78
Ypsomed Holding AG SFr.90.65 CHF +0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation BJCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOJECT MEDICAL TECHNOLOGIES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at